ArticleOncoTargets and therapy2022

Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer.

Meng-Chin Ho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.